Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The real problem is that management has gone stealth. They did one press release in July about the project, then some BS releases about social media and a hotshot advisor. If you call the company no one returns a call. They need IR and they need to get some news out to let shareholders know they are working. Also to attract new shareholders.
It might be trading in oversold territory on the chart, but if someone has stock, and they want out, it's going lower. I am still holding mine and I'm going to buy more.
I can't tell you why a trader trading stock for a market maker trades the way he trades. What I can tell you is that market makers have to file net capital reports with FINRA. There is no way ANY brokerage firm is going to leave themselves open and exposed to losses for a few thousand dollars profit.
Agreed.
It's not a short. Someone has stock to sell. Like I say, hopefully they are out, or close to being out. Probably someone who was in the deal, but had a disagreement with management. We can only speculate. CDEL shows 7297 shares at $1.05. That's the seller. There is also 1162 for sale at $1.05 through CSTI. CSTI shows up when I put a trade in at TD Ameritrade.
My experience is anytime there is selling, like we are seeing here, it's someone who has stock, or has been promised stock. Hopefully whoever it is gets out of their position before PLYN goes to low. We now need a 50% move in the bid to get people who bought at the offer yesterday back to break even.
The calm before the storm? PLYN is definitely quiet.
What do you mean by news hits?
Stock promotion megaphone just added on OTCMarkets.com. Looks like the regulators are watching. This one is over.
Signs of life returning to NCRA. I'm noticing the stock is trading daily. Plus a 9/2 news release says NCRA has a "next-generation of commercially operational Recirculating Aquaculture Systems (RAS) designed to improve productivity and sustainability in commercial aquaculture." The new tanks have an improved oxygenation system, which allows approximately 50% more fish to be raised in the tanks, and makes the transport of fish more convenient.
Why is everyone on this board living in the past? In this report filed 8/31/2020 https://backend.otcmarkets.com/otcapi/company/financial-report/256770/content it says Bob Rakow resigned and there is a new CEO in charge. It's obvious from the 6/1/2020 press release CWNR merged with another company. It was a shell! A way to bring another company public! The new company will change the name and symbol and the press release says it will do a reverse split! There is no CWNR any more, or Bob Rakow! Only "public community oriented real estate redeveloper targeting economic and opportunity growth zones in secondary and tertiary value added markets" in the process of reorganizing the cap structure.
I agree with you 100%, and that's why I'm in. You never see OTC stocks sucking up $25,000 and $30,000 sells. Something is definitely cooking here!
I agree with you 100%. There is no question the shorts are trying to hold VBIV down. Then there was some ridiculous article from Benzinga that claimed they could tell there is a downward bias in the stock price from some activity in some options trades. Obviously paid to try to take the stock lower. One big news release sends VBIV through $6.00. I'll dance naked in the street, if we don't see it.
I called and left a message for the CEO, but he didn't think returning a shareholder's call would be a good use of his time. I bought this back in June, and since then, we had one announcement about a shark tank guy coming on as an advisor. Totally non business related. If any of you guys on this board know the CEO, you might want to let him know he needs to put some news out about the progress the Company is making on its gold project.
I'm in! Raymond James analyst Steven Seedhouse has a price target of $9.00. $50 million in cash. 12.7 million share short position. VBIV is not a one trick pony with VBI-2900. The Company still has HBV and glioblastoma vaccine candidates if the China Virus vaccine doesn't work. I'm in!
I'm hearing there is some big news coming on PLYN.
Patience is a virtue!
I've been in since June, so don't tell me about patience. Also, don't tell me what to do with my stock and that buyers are lined up. I have a level 2 and can see PAUL on the bid for 100 shares. Then GTSM for 100 at $1.19, then CSTI for 100 at $1.12.
The stock needs some buyers.
Zero buying. I thought this stock was supposed to move?
$4 billion! That's how much 2 million ounces of gold is worth if gold moves $25 higher. "Palayan is targeting an initial 2 million ounce gold resource, with total resource potential believed to be 5+ million ounces of gold over 7 separate gold zones."
Just give me 10% of that and I have 10 times my money!
PLYN could be the next 10-bagger. The Historical Estimate at Kokkus #1 is estimated to be at least 199,000 ounces of gold. 199,000 ounces of gold x today's price of $1,974.00 is $392,826,000.00 worth of gold. Even 10 percent of that is $39.3 million, which is basically the market cap of the entire company right now! Not only that, but Kokkus #2 appears to be even bigger than Kokkus #1. You hear that booming noise? That's me pounding the table! Haha!
PLYN looks like a great low float play. I'm in and plan to buy more.
Shows $0.0001 bids. Big coronavirus press release and now nothing. Someone must have had some stock to sell?
KYNC is a scam. They haven't done one thing they said they would do. Nothing but false press releases. Beware! You have been warned!
Never, have I ever seen ridiculous press releases like this. Just like the the old saying goes, "There is no honor among thieves."
KYN CLARIFIES THE VALIDITY OF ITS BOARD OF DIRECTORS | 01/17/2020
KYNC ANNOUNCES TERMINATION OF PHIL SANDS AS CEO | 01/16/2020
KYN Capital Group and Shefford Capital Partners Agree to Part Ways | 12/11/2019
You hit the nail on the head.
...kinda makes the whole idea of OTC penny stocks seem entirely pointless.
Ehave and BurstIQ Enter Into a Partnership Expanding Ehave Dash Bringing HIPAA & GDPR Compliant Data Storage to Healthcare
Ehave, Inc. to Present Ehave Dashboard at the 2020 HIMSS Global Health Conference & Exhibition, March 9-13, 2020 in Orlando
MIAMI, FL / ACCESSWIRE / February 6, 2020 / Ehave, Inc., (OTC PINK:EHVVF) (the "Company"), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced today the Company expanded its partnership with BurstIQ to bring Ehave's dashboard compliant with both HIPAA and GDPR standards using BlockChain technology. Last month Burst IQ announced it had successfully passed its 2019 independent SSAE 18, SOC 2 Type 2 audit. This is the second annual SOC audit that the company has undergone. In both years, the company's blockchain-based data platform has passed the audit with zero exceptions - the highest level possible. BurstIQ remains the only blockchain platform to receive compliance certification under SOC 2 Type 2 audit requirements.
Additionally, Alfred Farrington II, Chief Information Officer, will speak at the 2020 HIMSS Global Health Conference & Exhibition being held at the Orange County Convention Center in Orlando, FL on March 9-13, 2020. Mr. Harrington will be presenting on the advanced capabilities of the Ehave dashboard and the multitude of benefits it provides to researchers and health care professionals. Ehave shareholders are invited to attend Mr. Farrington's presentation and can call or email Investor Relations for more information. Additional details on the HIMSS Global Health Conference and Exhibition is available at https://www.himssconference.org.
Nearly 45,000 attendees from more than 90 countries are expected to attend the conference. This year's speakers include: Arianna Huffington, Founder & CEO of Thrive Global; Chris Christie, Former Governor of the State of New Jersey; Gianrico Farrugia, President and CEO of the Mayo Clinic; Garth Graham, Vice President, Community Health & Impact, CVS Health President, Aetna Foundation; George Halvorson, Chairman and CEO of Institute For Intergroup Understanding, Rod Hochman, President and CEO of Providence; Terry McAuliffe, Former Governor of the State of Virginia and Former Chairman of the Democratic National Committee; Karen Murphy, Chief Innovation Officer of Geisinger; Alex Rodriguez, Former MLB All-Star and Founder & CEO of A-Rod Corp; Donald Rucker, National Coordinator for Health Information Technology @ Department of Health and Human Services; and Laura Wilt, SvP & CIO of Ochsner Health System.
About Ehave, Inc.
Ehave, Inc. (EHVVF) is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. For more information visit: www.ehave.com.
About Burst IQ
BurstIQ is the leading provider of blockchain-enabled data network solutions for the healthcare industry. The company's private, permissioned data network allows health systems, payers, digital health companies, pharma & life science companies and governments to unlock the full potential of health-related data. The platform uses blockchain, Big Data, machine intelligence, and granular data ownership and consent to build longitudinal profiles of people, places, and things and empower the interactions between them. The result is a global, secure data network that allows health systems, payers, digital health companies, pharma & life science companies and governments to collaborate, share, analyze and unlock a deeper understanding of the diverse factors that influence health.
Forward-Looking Statement Disclaimer
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company's research, manufacturing and other development efforts; (ii) the Company's ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company's products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company's industry and introduction of competing products; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.'s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website, http://www.sec.gov.
For Investor Relations, please contact:
Gabe Rodriguez
Phone: (623) 261-9046
Email: ir@ehave.com
SOURCE: Ehave, Inc.
It's difficult for a company with a $0.01 stock price to raise any money. CANB has Wainright raising them money when the company is recapitalized. Without money to expand, any company ould go under. That being said, look at the cannabis stocks three years ago. Canopy went from under $4 to over $55. Cannabis stocks will get hot again. Canbiola just has to keep growing and it's going to be a lot harder on the OTC than NASDAQ.
Investors don't get how huge yesterday's release was. These are not just new products. Canbiola is making products for a pretty good size company to sell through their distribution network.
There is no question they are doing a 1 for 300 to bring the price up, so they can get on NASDAQ. The big difference here is that most investors are used to companies reversing because tocic debt holders have driven their price down. After the reverse, they drive it down again. Canbiola shouldn't have that issue and they are probably doin the reerse in conjunction with a financin by Wainright that they filed an 8-k on. This one could surprise us.
Key Financial Highlights
Q1 2019 revenues increased quarter over quarter from the prior year by 741% to $517,160 with a gross profit margin of 49%.
We posted an operating loss of $1.2 million for Q1 2019, which included $0.8 million in non-cash stock-based compensation.
Q2 revenues increased quarter over quarter from the prior year by 311% to $633,579 with a gross profit margin of 52.8%.
We posted an operating loss of $1,435,289 for Q2 2019, which included $959,948 in non-cash stock-based compensation.
Closed $3,936,700 cash raised subsequent to the end of the quarter in a Reg D offering.
Q3 2019 revenues increased quarter over quarter from the prior year by 277% to $615,422 with a gross margin of 77%.
We posted an operating loss of $935,264 for Q3 2019, which included $602,823 in non-cash stock-based compensation.
Key Business Highlights for 2019
Launched Pure Leaf Oil as its Consumer Brand from the acquisition of Pure Health Products LLC in December 2018.
Attained Registration in the GSA’s System for Award Management and Department of Defense.
Finalized Asset Purchase Agreement with Seven Chakras, Inc.- the Company’s Spa Line of products.
Completed a 300% increased investment in its Duramed division to combat the pain management and opioid crisis.
Conducted its Annual Shareholder Meeting on June 14 with over 200 in attendance.
Opened a new wholly-owned operating division – NY Hemp Depot LLC to develop cultivation operations under a new operating license.
The first products became available via Amazon.com.
Launched in test and development mode a dedicated Canbiola-branded CBD dispensing machine.
Approved a reverse stock split with intent to satisfy one criterion for a potential NASDAQ listing.
Launched Canbiola Turmeric & Ginger Pure Hemp Extract in 30MG capsules, Canbiola's first capsule hemp extract product.
Presented at both the H.C. Wainwright 21st Annual Global Investment Conference in September and the 12th Annual LD Micro Conference in December.
Executed an agreement for an all-stock transaction to acquire 51% of Green Grow Farms Inc. from Iconic Brands, Inc.
Also in 2019, Canbiola added key personnel including the appointment of Senator Ron Silver, James Murphy, and Alger Boyer Jr. to its Board of Directors to create an independent Board, satisfying a requirement for potential NASDAQ listing. Steven Medina Esq., Jason Winn, Dr. Mehran Peter Ghazvini, David Woycik, Jr., and John Bach joined our Corporate Advisory Board, while NFL Great Leonard Marshall joined Canbiola's Sports Advisory Board.
Canbiola, Inc. Announces 2019 Highlights and 2020 Plans for Expansion
Why is everyone unhappy about Canbiola spending money on IR? According to the white papers on OTC Markets website, the average small-cap IR department has a budget of $208,000. OTC Markets white papers also recommend paid for research, and this Harbinger report is first class and written by a CFA. It looks to me like Canbiola is going to conferences, hiring newsletters, research guys, and other IR people who can introduce them to investors. That's what they're supposed to be doing.
https://www.irmagazine.com/research-reports/small-cap-investor-relations-best-practice-making-most-ir
That's a profit and loss model. Fourth quarter hasn't come out yet, which is why the analyst says the numbers are projections.
CEO Ben Kaplan took over because he saw the opportunity. After the reverse there can't be much in the float. Kaplan probably has a lot, but he can't sell because he's an officer. After today, I think Ehave miht go over a dollar.
Ehave is really on to something with psychedelic medicine. Mental health should be somethin all of us are talking about.
You know what they say, Even a blind squirrel finds a nut every now and then! Seriously, I'm bullish on CANB and think this seller who has been hanging over the market like a black cloud the last few months is gone.
I googled it and this report Deloitte did last year came up. It's pretty impressive and doesn't say anything about the market being in a state of surplus. Deloitte says "The edibles market alone is estimated to be worth at least $1.6 billion a year in Canada, with cannabis-infused beverages adding a further $529 million," said Jennifer Lee, a partner and Deloitte Canada's Cannabis National Leader, and Consumer Advisory and Analytics Practice National Leader. Deloitte estimates next round of cannabis legalization will create a new $2.7-billion market in Canada
That's just Canada. I don't have any numbers for the US.
Replying to my own post predicting CANB trades through $0.02 this week. It looks like the big seller who has been hanging over the market is gone. Looking at the chart, I think we could see mid $0.03 range next few weeks. Let's hope they have great year end numbers to take us higher.
I think CANB goes through $0.02 this week. It seems like there is one seller in the stock.